

**A REVIEW OF TUBERCULOUS CASES
ADMITTED AT GIZA CHEST HOSPITAL
DURING THE PERIOD 2005-2009**

THESIS

SUBMITTED FOR FULLFILMENT OF MASTER
DEGREE IN CHEST DISEASES AND TUBERCULOSIS

by

MOHAMMAD IBRAHIM ABU EL-NASR
M.B.B.CH

SUPERVISED BY

PROF. MOHAMMAD ABDELSABOUR FARAMAWY
PROFESSOR OF CHEST DISEASES
FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY

Ass Prof. GEHAN MOHAMMAD EL-ASAAL
ASSISTANT PROFESSOR OF CHEST DISEASES
FACULTY OF MEDICINE
AIN SHAMS UNIVERSITY

AIN SHAMS UNIVERSITY
Faculty of medicine
2010

Acknowledgment

In the name of Allah, most gracious, most merciful.

Thanks to Allah, this work has been brought to light.

I would like to express my sincere thanks, deep gratitude, and extreme appreciation to Professor.Mohammad Abdelsabour, Professor of Chest Diseases, Faculty of Medicine, Ain Shams University, for his remarkable help, indispensable advice and encouragement throughout this work.

I wish to express my deep gratitude to Dr. Gehan Elassaf, Assistant Professor. of Chest Diseases, Faculty of Medicine, Ain Shams University, for her kind supervision, valuable advice, support, comments and remarks.

LIST OF CONTENTS

	<i>Page</i>
<u>INTRODUCTION</u>	1
<u>AIM OF THE WORK</u>	4
<u>REVIEW OF LITERATURE:</u>	
History of tuberculosis	5
Evolution of infection.....	17
Pathogenesis of tuberculosis	25
Immunopathology of tuberculosis	43
Latent Tuberculosis infection	46
Diagnosis of Pulmonary Tuberculosis	49
Preventive measures for tuberculosis	86
Management of tuberculosis.....	89
<u>MATERIALS AND METHODS</u>	118
<u>RESULTS</u>	121
<u>DISCUSSION</u>	133
<u>SUMMARY</u>	144
<u>RECOMMENDATIONS</u>	147
<u>REFERENCES</u>	149
<u>ARABIC SUMMARY</u>	

LIST OF ABBREVIATIONS

ADA: Adenosine Deaminase.
AFB: Acid-Fast Bacilli.
AIDS: Acquired Immune Deficiency Syndrome.
Am: Amikacin.
Amx/Clv: Amoxicillin/Clavulanate.
ARI: Annual Risk of Infection
ATP: Adenosine Tri-Phosphate
ATS: American Thoracic Society
BC: Before Christ
Bactec: Becton Automated Culture Technology
BCG: Bacille Calmette-Guerin.
CD: Cluster of Differentiation
CDC: Centers for Disease Control & Prevention.
CDR: Case Detection Rate
CFT: Complement Fixation Tests.
Cfx: Ciprofloxacin.
CFU: Colony Forming Unit.
CFP-10: Culture Filtrate Protein-10
Cfz: Clofazimine.
Clr: Clarithromycin.
Cm: Capreomycin.
CPT: chest physiotherapy
CR: Complement Receptor
Cs: Cycloserine.
CT: Computed Tomography
DARQs: Diarylquinolines
DOTS: Direct Observed Therapy Strategy.
DRS: Drug Resistance Surveillance
DST: Drug Susceptibility Testing.
E: Ethambutol.
EF: Efficiency.
ELISA: Enzyme-Linked Immuno-Sorbent Assay.
ELISPOT: Enzyme-Linked Immunospot.
EMB: Ethambutol.
ESAT-6: Early Secretory Antigenic Target-6
Eto: Ethionamide.
Ex-PTB: Extra-Pulmonary Tuberculosis
FOB: Fiber-Optic Bronchoscopy
Gfx: Gatifloxacin
HIO: Health Insurance Organization
HIV: Human Immunodeficiency Virus.
IgA: Immunoglobulin A
IM: Intramuscular.
iNOS: inducible Nitric Oxide Synthase
IL: Interleukin
INF γ : Interferon gamma.
INH: Isonicotinic acid hydrazide
Km: Kanamycin.
LAM: Lipoarabinomannan

LCR: Ligase chain reaction.
Lfx: Levofloxacin.
LI: Lytic Index
LiPA: Line Probe assay.
LJ: Lowenstein-Jensen.
LTBI: Latent Tuberculosis Infection
Lzd: Linezolid.
M: Mycobacterium.
MAC: Mycobacteria avium-intracellulare complex.
MDR-TB: Multi-Drug-Resistant Tuberculosis.
Mfx: Moxifloxacin.
MGIT: Mycobacterial Growth Indicator Tube.
MIC: Minimal Inhibitory Concentration.
MOHP: Ministry of health and population.
MOTT: Mycobacteria Other Than Tubercle bacilli.
MTB: Mycobacterium Tuberculosis
NAAT: Nucleic Acid Amplification Tests.
NO: Nitric Oxide
NTM: Non Tuberculous Mycobacteria.
NTP: National Tuberculosis Programme
Ofx: Ofloxacin.
P: Pyrazinamide.
P-A: Postero-anterior.
PAS: Para-AminoSalicylic acid.
PBS: Phosphate Buffer Saline
PCR: Polymerase Chain Reaction.
PI: Phagocytic Index
PM: Proportion Method.
PPD: Purified Protein Derivative.
PTB: Pulmonary Tuberculosis
Pto: Protionamide.
PZA: Pyrazinamide.
QFT: QuantiFERON-TB test
RIF: Rifampicin.
RMP: Rifampicin.
RNA: Ribonucleic acid.
S: Streptomycin.
SCC: Short Course Chemotherapy.
SD: Standard Deviation.
SM: Streptomycin.
TACO: Tryptophan Aspartate Coat Protein
TB: Tuberculosis.
Th: Thioacetazone.
Th1: T-helper 1 lymphocyte
Th2: T-helper 2 lymphocyte
TLR: Toll-Like Receptor
TNF α : Tumour Necrosis Factor alpha.
TST: Tuberculin Skin Test
TTD: time to detection
XDR-TB: Extensively-Drug-Resistant Tuberculosis
WHO: World Health Organization

LIST OF FIGURES

<i>Figure</i>	<i>Subject</i>	<i>Page</i>
(1)	A vertebral Bone Affected by Tuberculosis	5
(2)	Robert Koch (1843-1910)	7
(3)	Estimated global prevalence, mortality, and incidence rates, 1990-2006	12
(4)	Estimated TB incidence rates, by country, 2006.	13
(5)	DOTS coverage MOHP facilities 1997-2000	16
(6)	detection rate of new smear positives	17
(7)	Rt. upper lobe shadowing of pulmonary TB	60
(8)	Cavitary lesion of Pulmonary TB in CT chest.	60
(9)	Smear positive for acid fast bacilli.	64
(10)	T SPOT-TB procedure	77
(11)	Phage amplification technology	82
(12)	Sanatorio Pineta del Carso, Italy	94
(13)	Total number of tuberculous cases and their percentage per total number of patients admitted to the hospital during the period from 2005 to 2009	122
(14)	Classification of the tuberculous cases according to the sex	123
(15)	Classification of the tuberculous cases according to the age of the patients	124
(16)	Age Distribution of the tuberculous cases	124
(17)	Classification of the tuberculous cases according to the state at the time of presentation	126

(18)	the number of positive sputum by direct smear and their percentage per total number of the tuberculous cases	127
(19)	the number of tuberculous patients in each year and the no. of cases those were diagnosed by sputum culture from them	128
(20)	classification of the tuberculous cases according to the site of the lesion	130
(21)	classification of the discharged patients according to results of sputum examination by direct smear	131
(22)	Classification of patients according to treatment category	132

LIST OF TABLES

<i>TABLE</i>	<i>Subject</i>	<i>Page</i>
(1)	Recommended doses for first-line antituberculosis drugs	97
(2)	Recommended doses for second-line anti-tuberculosis drugs	97
(3)	Recommended standardized treatment regimens of TB according to NTP 2006	101
(4)	Fixed dose combinations of anti-TB drugs, NTP 2006	102
(5)	The dose of 4-FDCs according to the weight	102
(6)	The recommended regimen for MDR-TB	112
(7)	The Toxicities of the second line drugs and their management	114
(8)	Total number of tuberculous cases and their percentage per total number of patients admitted to the hospital during the period (2005-2009)	121
(9)	Classification of the tuberculous cases according to the sex	122
(10)	Classification of the tuberculous cases according to the age of the patients	123
(11)	Classification of the tuberculous cases according to the state at the time of presentation	125
(12)	The number of positive sputum by direct smear and their percentage per total number of the tuberculous cases	126
(13)	The number of patients diagnosed by culture examination and their percentage per number of tuberculous patients	127
(14)	Classification of the tuberculous cases according to the site of the lesion	129
(15)	Classification of the discharged patients according to results of sputum examination by direct smear	130
(16)	Classification of patients according to treatment category	131

LIST OF CONTENTS

	<i>Page</i>
<u>INTRODUCTION</u>	1
<u>AIM OF THE WORK</u>	4
<u>REVIEW OF LITERATURE:</u>	
History of tuberculosis	5
Tuberculosis; a global view.....	9
Evolution of infection.....	17
Pathogenesis of tuberculosis	25
Pathological types of TB:.....	34
Immunopathology of TB.....	43
Latent Tuberculosis infection	46
Diagnosis of Pulmonary Tuberculosis	49
Preventive measures for tuberculosis	86
Management of tuberculosis.....	89
<u>MATERIALSAND METHODS</u>	118
<u>RESULTS</u>	121
<u>DISCUSSION</u>	133
<u>SUMMARY AND CONCLUSION</u>	144
<u>RECOMMENDATIONS</u>	146
<u>REFERENCES</u>	148
<u>ARABIC SUMMARY</u>	

Introduction

Tuberculosis (TB) is a bacterial disease spreads by infectious air borne droplets containing *Mycobacterium tuberculosis* (occasionally *Mycobacterium bovis* or *africanum*) (*Koch, 1932*). Once the organism is inhaled, it travels via the airways to the pulmonary parenchyma where it is deposited. Although the organism may be deposited in any lobe, a predilection for the lower lobes exists (*Tara, 2005*).

The organism is ingested by alveolar macrophages, which then attempt to phagocytose the bacilli. As a result of the natural defenses of the tubercle bacillus, alveolar macrophages may be unsuccessful in attempting to completely destroy the bacilli, which then lie dormant within the macrophage. As a consequence, bacilli often remain viable within the macrophages in immunocompetent individuals. Subsequently, bacilli may travel via the pulmonary lymphatics, or they may enter the vascular system and seed distant sites such as the liver, spleen, or bone marrow (*Tara, 2005*).

In most immunocompetent individuals, macrophages are successful in containing the bacilli, and the infection is self-limited and often subclinical. The contained infection in immunocompetent hosts is called primary tuberculosis. In some patients, pulmonary macrophages are unable to contain the bacilli and are overwhelmed, leading to a clinically apparent infection. This is more common in patients who are immunocompromised, notably the population with HIV/AIDS. This form of tuberculosis is called progressive primary tuberculosis. Patients with progressive primary tuberculosis may present with pulmonary manifestations (often with miliary tuberculosis) or with manifestations of systemic or disseminated disease (*Tara, 2005*).

Patients who are exposed to T.B bacilli for the first time have pathologic, roentgenologic, and clinical features different from those who have reactivation of previous disease. As a consequence, it is logical to consider the disease processes under the separate headings of primary and post-primary tuberculosis (*Fraser et al., 1994*)

Approximately 80% of tuberculosis patients have pulmonary disease and the remainder have extrapulmonary disease with or without pulmonary component. Among HIV-coinfected persons, this association is drastically altered and may even be reversed. The sites where extrapulmonary tuberculosis is most commonly seen, in declining order of frequency, are the lymph nodes, pleura, genito-urinary tract, and the bones and joints. Meningeal tuberculosis accounts for approximately 1% of cases (*Niederman et al., 2001*)

Postprimary (reactivation) tuberculosis is seen in patients in whom the initial infection was contained successfully by the pulmonary macrophages, with bacilli remaining viable within the macrophages. Infection results when the host's immune status (T cells) is compromised. This form may appear in the elderly population, for example (*Tara, 2005*).

Multi-drug-resistant tuberculosis (MDR-TB) is an increasing global problem, the extent & burden of which varies significantly from country to country & region to region (*Ormerod, 2005*).

The prevalence rate of new cases of multi-drug-resistant tuberculosis (MDR-TB) was 2.2% while that of the previously treated tuberculous cases, which were discovered to be multi-drug-resistant, was 38%. (*WHO, 2004*)

A patient is determined to have a MDR-TB only through laboratory confirmation of in vitro resistance to at least Isoniazid & Rifampicin (***WHO TB report 2005***).

More than eight million people develop active TB annually, and approximately two million die from the disease each year. The WHO estimate that there are more than 15 million people living with TB. In 2003, out of estimation 8.8 million new TB cases worldwide, 3.9 million were diagnosed by laboratory testing and 674,000 also were HIV+ve. An estimated 1.7 million people died of TB in 2003, 22 % of whom were co-infected with HIV. Those with active TB who receive no treatment can infect an average of 10 to 15 people annually. Although TB is curable, it kills 5000 people every day, 98% of deaths are in developing world affecting mostly young adults in their most productive years. (***WHO TB report, 2005***).

Aim of the Work

The aim of this study is to review the tuberculosis cases admitted to Giza chest hospital during the last five years (2005-2009) in order to evaluate the National Tuberculosis Program application in Egypt.

Tuberculosis

History of Tuberculosis

It is presumed that the genus *Mycobacterium* originated more than 150 million years ago (**Daniel 2006**). An early progenitor of *M. tuberculosis* was probably contemporaneous and co-evolved with early hominids in East Africa, three million years ago. The modern members of *M. tuberculosis* complex seem to have originated from a common progenitor about 15,000 - 35,000 years ago (**Gutierrez et al. 2005**).



Figure (1): A vertebral Bone Affected by Tuberculosis

The term phthisis/consumption appeared first in Greek literature. Around 460 BCE, Hippocrates identified phthisis as the most widespread disease of the times, and noted that it was almost always fatal. Due to common phthisis-related fatalities, he wrote something no doctor would dare write today: he warned his colleagues against visiting TB patients in late stages of the disease, because their inevitable deaths might damage the reputations of the attending physicians (**Palomino et al. 2007**).